Tri Locum Partners LP: VERTEX PHARMACEUTICALS INC (VRTX): Quarterly 13F Position History
As of Q2 2026, Tri Locum Partners LP reported 201,791 shares of VERTEX PHARMACEUTICALS INC (VRTX), worth $100.2M and representing 12.3% of its 13F equity book. Quarter-over-quarter share count change: + 72,477 (+56.0%) . The position first appeared in Q2 2023 and has been disclosed across 13 13F-HR filings in Pactolio's tracked window.
- 201,791Shares Held (Latest Filing)
- $100.2MReported Market Value (Latest Filing)
- 12.3%Portfolio Weight (% of 13F Equity Book)
- +72,477Quarter-over-Quarter Share Change
- +$42.5MQuarter-over-Quarter Value Change
- 201,791Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 13 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q2 2026 | 201,791 | +72,477 | +56.0% | $100.2M | 12.3% | $496.7 |
| Q1 2026 | 129,314 | +129,314 | – | $57.7M | 8.1% | $446.5 |
| Q4 2025 | 0 | 0 | – | $0 | 0.0% | – |
| Q3 2025 | 0 | 0 | – | $0 | 0.0% | – |
| Q2 2025 | 0 | 0 | – | $0 | 0.0% | – |
| Q1 2025 | 0 | 0 | – | $0 | 0.0% | – |
| Q4 2024 | 0 | 0 | – | $0 | 0.0% | – |
| Q3 2024 | 0 | 0 | – | $0 | 0.0% | – |
| Q2 2024 | 0 | 35,598 | -100.0% | $0 | 0.0% | – |
| Q1 2024 | 35,598 | +35,598 | – | $14.9M | 5.2% | $418.0 |
| Q4 2023 | 0 | 0 | – | $0 | 0.0% | – |
| Q3 2023 | 0 | 24,597 | -100.0% | $0 | 0.0% | – |
| Q2 2023 | 24,597 | – | – | $8.7M | 3.2% | $351.9 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares, a quarter-end mark rather than the manager's cost basis. See the full methodology document for the normalization rules.
When did Tri Locum Partners LP first disclose a VRTX position in 13F-HR filings?
Tri Locum Partners LP first reported VERTEX PHARMACEUTICALS INC (VRTX) on its 13F-HR filing for the period ending 2023-06-30 (Q2 2023). The position has appeared on 13 reported quarters within Pactolio's tracked window.
What was Tri Locum Partners LP's most recent quarter-over-quarter share-count change in VRTX?
Between Q1 2026 and Q2 2026, Tri Locum Partners LP added 72,477 shares of VRTX (+56.0%), bringing the total reported position to 201,791 shares at a market value of $100.2M.
Does the implied price-per-share represent Tri Locum Partners LP's cost basis in VRTX?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.